4.4 Article

YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance

Journal

DEVELOPMENTAL BIOLOGY
Volume 475, Issue -, Pages 205-221

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ydbio.2020.12.018

Keywords

YAP1; Gene fusions; YAP1 fusion; Cancer; Hippo signaling pathway

Funding

  1. U.S. National Cancer Institute [R01CA188452, R01CA234050, U54CA243125-01]
  2. The Ben and Catherine Ivy Foundation

Ask authors/readers for more resources

YAP1 is a crucial transcriptional co-activator involved in both normal tissue homeostasis and cancer development. Its activity is regulated by various mechanisms such as the Hippo signaling pathway and miRNAs, and different therapeutic strategies targeting YAP1 functions are being explored.
YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available